{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:53:10Z","timestamp":1771455190089,"version":"3.50.1"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>In places where hepatitis B virus (HBV) infection is endemic, itis often necessary to give chemotherapy to or perform bone marrowtransplantation for cancer patients who are also chronic HBV carriers.When standard chemotherapy was given to lymphoma patients, elevation ofliver transaminases was observed in nearly half of those who werechronic HBV carriers. Ten percent of them became jaundiced, and theoverall liver-related mortality was about 5%. There is currently noreliable way to predict the severity of HBV reactivation afterchemotherapy. The risk is probably higher when the chemotherapy used issignificantly immunosuppressive and the viral load in the liver ishigh. Different strategies have been used in an attempt to reduce therisk of HBV reactivation after chemotherapy, but they have not beenvery successful. Further studies will be required to determine theimpact of newly available antiviral agents that are active against HBV.<\/jats:p><jats:p>Recipients who are carriers of HBV or who receive hepatitis B surfaceantigen (HBsAg)-positive marrow are at increased risk of hepatitisB-related morbidity and mortality after bone marrow transplantation(BMT). There is evidence to suggest that prophylactic use of an activeantiviral agent, such as famciclovir, may result in a significantdecrease in the incidence and severity of HBV reactivation after BMT.Sustained serologic clearance of chronic HBV infection has also beenreported in many HBsAg-positive marrow recipients receiving hepatitis Bsurface antibody-positive marrow from their allogeneic donors. Thereseems to be a transfer of both humoral and cellular immunity againstHBV from donors to recipients.<\/jats:p><jats:p>Further prospective studies are required to define the best approach tomanage HBsAg-positive cancer patients receiving chemotherapy or BMT. Itis recommended that all cancer patients be checked for their hepatitisB status before receiving chemotherapy or a bone marrow transplant,especially if they reside in or come from endemic areas of HBVinfection.<\/jats:p>","DOI":"10.1200\/jco.1999.17.1.394","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:52:05Z","timestamp":1487919125000},"page":"394-394","source":"Crossref","is-referenced-by-count":140,"title":["Chemotherapy and Bone Marrow Transplantation for Cancer Patients Who Are Also Chronic Hepatitis B Carriers: A Review of the Problem"],"prefix":"10.1200","volume":"17","author":[{"given":"Raymond","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George K.K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. L.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0394","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114681"},{"key":"R2-0394","doi-asserted-by":"crossref","unstructured":"Lok ASF: Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 10:46,1992-52,","DOI":"10.1159\/000171343"},{"key":"R3-0394","doi-asserted-by":"crossref","unstructured":"Wands JR: Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 2:979,1975, (letter)","DOI":"10.1016\/S0140-6736(75)90391-8"},{"key":"R4-0394","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90599-G"},{"key":"R5-0394","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900080504"},{"key":"R6-0394","unstructured":"Lau JYN, Lai CL, Lin HJ, et al: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 36:47,1989-54,"},{"key":"R8-0394","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0"},{"key":"R9-0394","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90934-2"},{"key":"R10-0394","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90337-X"},{"key":"R11-0394","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100502"},{"key":"R12-0394","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1995.tb00066.x"},{"key":"R13-0394","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250144"},{"key":"R14-0394","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332501"},{"key":"R15-0394","doi-asserted-by":"crossref","unstructured":"Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir. Hepatology 26:216,1997-223,","DOI":"10.1053\/jhep.1997.v26.pm0009214473"},{"key":"R16-0394","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1996.tb00098.x"},{"key":"R18-0394","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008206519571"},{"key":"R19-0394","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700744"},{"key":"R20-0394","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80363-7"},{"key":"R21-0394","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199004000-00011"},{"key":"R22-0394","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199504270-00011"},{"key":"R23-0394","doi-asserted-by":"crossref","unstructured":"Lok ASF, Liang RHS, Chung HT: Recovery from hepatitis B. Ann Intern Med 116:957,1992, (letter)","DOI":"10.7326\/0003-4819-116-11-957_2"},{"key":"R24-0394","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90664-X"},{"key":"R25-0394","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250631"},{"key":"R26-0394","unstructured":"Locasciulli A, Alberti A, de Bock R, et al: Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: A survey from the European Bone Marrow Transplantation (EBMT) Group\u2014Infectious Diseases Working Party. Bone Marrow Transplant 14:833,1994-837,"},{"key":"R27-0394","unstructured":"Martin BA, Rowe JM, Kouides PA, et al: Hepatitis B reactivation following allogeneic bone marrow transplantation: A case report and review of the literature. Bone Marrow Transplant 15:145,1995-148,"},{"key":"R29-0394","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.1.195.195"},{"key":"R30-0394","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.3236.3236"},{"key":"R31-0394","unstructured":"Chen PM, Fan S, Liu JH, et al: Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 58:183,1993-188,"},{"key":"R32-0394","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1995.tb01039.x"},{"key":"R33-0394","unstructured":"Appleton AL, Sviland L, Peiris JS, et al: Role of target organ infection with cytomegalovirus in the pathogenesis of graft-versus-host disease. Bone Marrow Transplant 15:557,1995-561,"},{"key":"R34-0394","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.7.1998.1998"},{"key":"R35-0394","unstructured":"Appleton AL, Sviland L: Pathogenesis of GVHD: Role of herpes viruses. Bone Marrow Transplant 11:349,1993-355,"},{"key":"R36-0394","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb31058.x"},{"key":"R37-0394","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1699"},{"key":"R38-0394","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80307-3"},{"key":"R40-0394","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280241"},{"key":"R41-0394","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701148"},{"key":"R43-0394","unstructured":"Fan FS, Tzeng CH, Yeh HM, et al: Reverse seroconversion of hepatitis B virus infectious status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant 10:189,1992-191,"},{"key":"R44-0394","doi-asserted-by":"crossref","unstructured":"Celis E, Kung PC, Chang TW, et al: Hepatitis B virus-reactive human T lymphocyte clones: Antigen specificity and helper function for antibody synthesis. J Immunol 132:1511,1984-1516,","DOI":"10.4049\/jimmunol.132.3.1511"},{"key":"R45-0394","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.6.1565"},{"key":"R46-0394","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.3.751"},{"key":"R47-0394","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.23.10445"},{"key":"R48-0394","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118592"},{"key":"R49-0394","doi-asserted-by":"crossref","unstructured":"Ilan Y, Nagler A, Adler R, et al: Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18:246,1993-252,","DOI":"10.1016\/0270-9139(93)90003-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.1.394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:26:22Z","timestamp":1692699982000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.1.394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1200\/JCO.1999.17.1.394"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.1.394","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}